How Biotech Went From ‘No Way’ to Payday in the Cannabis Business

Genetic engineers want to make bio-pot, for fun and health, but their venture could backfire if they help create a public health menace

Illustration: Saiman Chow

By Antonio Regalado

Last fall John Melo, the CEO of the synthetic-biology company Amyris, traveled to…

This story is just a click away.

Sign up for a free Medium account to read this story from MIT Technology Review. Plus, get one more story in your member preview this month.

Already have an account? Sign in

This story is just a click away.

Sign up for a free Medium account to read this story from MIT Technology Review. Plus, get one more story in your member preview this month.
Already have an account? Sign in